Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Nov 6 - Nov 11
Tirzepatide (Mounjaro) is a related but distinct drug, a dual GIP/GLP-1 receptor agonist where the primary target is the GIP receptor with additional GLP-1 activity, making it pharmacologically different from pure GLP-1 drugs like semaglutide
GLP-1s offer a promising pathway to lasting weight loss, but reaching and maintaining your goal requires time, consistency, and dedication
The authors estimate that between 1.3 and 2.1 million people living in Canada may meet the Canadian Cardiovascular Society criteria for type 2 diabetes patients eligible to use GLP-1RAs or SGLT2is
Recommend a suspension, not drops, to prevent blurred vision that could worsen his migraines C
For more information and details about eligibility and restrictions, visit or
